# PyramIDH (NCT06465953)

> Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06465953
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Institut de Recherches Internationales Servier
- Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes (MDS)
- Interventions: Ivosidenib; Azacitidine
- Enrollment: 48
- Primary outcome: Number of participants achieving CR and PR by 4 months

## Indexed commentary on PyramIDH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pyramidh-nct06465953